Avalo Therapeutics Inc
AVTX
Market Cap$94.75M
Close$
$12.16
154.5% upside
Current Fair Value
154.5% upsideUndervalued by 154.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $94.75 Million |
|---|---|
| Enterprise Value | $-29,616,370.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-113.58 |
| Beta | 1.09 |
| Outstanding Shares | 1,034,130 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.28 |
|---|---|
| PEG | 0.28 |
| Price to Sales | - |
| Price to Book Ratio | 0.04 |
| Enterprise Value to Revenue | -67.16 |
| Enterprise Value to EBIT | 0.62 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Avalo Therapeutics Inc
31 employeesCerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...